Preclinical research suggests that interleukin-10 (IL-10) is associated with susceptibility to and severity of systemic lupus erythematosus. Chronic cutaneous lupus erythematosus is thought to be immunogenetically different from systemic lupus erythematosus. We hypothesized that high innate production of IL-10 underlies systemic but not chronic cutaneous lupus erythematosus.
Methods
IL-10 production was determined after endotoxin stimulation of whole-blood samples. In whole-blood samples, disease activity and medication influence the IL-10 production in patients. Therefore, healthy first-degree relatives of patients were evaluated. One hundred sixty-six first-degree relatives of patients with systemic lupus, 50 first-degree relatives of patients with chronic cutaneous lupus, and 133 control persons were studied. Innate IL-10 production of the patient was estimated as the mean IL-10 production of the unaffected relatives. Polymorphisms located −1082, −819, and −592 base pairs relative to the IL-10 gene were typed by allele-specific oligohybridization of polymerase chain reaction-amplified DNA fragments.
Results
IL-10 production was higher in the families of patients with systemic lupus than in the control families (1517±94 vs 1180±59 pg/mL; P=0.003). IL-10 production in the families of patients with chronic cutaneous lupus was similar to that in control families (1216±82 vs 1180±59 pg/ml; P=0.74). IL-10 production was also similar in families of patients with severe compared with nonsevere systemic lupus (P=1.0). The frequency of −1082/–819/–592 haplotypes GCC, ACC, and ATA was similar among patients and compared with the control persons (P=0.29).
Conclusions
High innate IL-10 production underlies susceptibility for systemic lupus erythematosus but not the severity of the disease. It is not related to chronic cutaneous lupus erythematosus.
RoussetF, GarciaE, DefranceT, PeronneC, VezzioN, HsuDH, KasteleinR, MooreKW, BanchereauJ. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A1992;89:1890–1893.
2.
LlorenteL, ZouW, LevyY, Richaud-PatinY, WijdenesJ, Alcocer-VarelaJ, Morel-FourrierB, BrouetJC, Alarcon-SegoviaD, GalanaudP. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med1995;181:839–844.
3.
IshidaH, MuchamuelT, SakaguchiS, AndradeS, MenonS, HowardM. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med1994;179:305–310.
4.
HahnBH. Systemic lupus erythematosus. In: IsselbacherKJ, BraunwaldE, WilsonJD, MartinJB, FauciAS, KasperDL, eds. Harrison's Principles of Internal Medicine. 13th ed. International Edition. New York: McGraw-Hill; 1994:1643–1648.
5.
JacobCO. Studies on the role of tumor necrosis factor in autoimmunity. J Autoimmun1992;5(suppl A):133–143.
6.
JacobCO. Tumor necrosis factor and interferon gamma: Relevance for immune regulation and genetic predisposition to autoimmune disease. Semin Immunol1992;4:147–154.
7.
CerveraR, KhamashtaM, FontJ, SebastianiGD, GilA, LavillaP, DomenechI, AydintugO, Jedryka-GoralA, de RamonE, GaleazziM, HagaH-J, MathieuA, HoussiauFA, IngelmoM, HughesG. Systemic lupus erythematosus. Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine (Baltimore)1993;72:113–124.
8.
DeapenD. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum1992;35:311–318.
9.
FreedmanBI, WilsonCH, SprayBJ, TuttleAB, OlorenshawIM, KammerGM. Familial clustering of end-stage renal disease in blacks with lupus nephritis. Am J Kidney Dis1997;29:729–732.
10.
MoserKL, NeasBR, SalmonJE, YuH, Gray-McGuireC, AsundiN, BrunerGR, FoxJ, KellyJ, HenshallS, BacinoD, DietzM, HogueR, KoelschG, NightingaleL, ShaverT, AbdouNI, AlbertDA, CarsonC, PetriM, TreadwellEL, JamesJA, HarleyJB. Genome scan of human systemic lupus erythematosus: Evidence for linkage on chromosome Iq in African-American pedigrees. Proc Natl Acad Sci U S A1998;95:14869–14874.
11.
ZuñigaR, NagS, ReveilleJD, et al. Allelic variants of Fc gamma RIA and Fc gamma RIIIA do not appear to be linked, but they both contribute to the risk for SLE nephritis in Mexican American Lupus. Arthritis Rheum1998;41:1498. Abstract.
12.
DuitsAJ, BootsmaH, DerksenRHWM, SpronkPE, KaterL, KallenbergCGM, CapelPJA, WesterdaalNAC, SpierenburgGTh, Gmelig-MeylingFHJ, van de WinkelJGJ. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum1995;39:1832–1836.
13.
SalmonJE, MillardS, SchachterLA, ArnettFC, GinzlerEM, GourleyMF, Ramsey-GoldmanR, PetersonMGE, KimberlyRP. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest1996;97:1348–1354.
14.
van der LindenMW, HuizingaTWJ, StoekenDJ, SturkA, WestendorpRGJ. Determination of TNF-a and IL-10 production in a whole blood stimulation system: Assessment of laboratory error and individual variation. J Immunol Methods1999;218:63–71.
15.
WestendorpRG, LangermansJA, HuizingaTW, EloualiAH, VerweijCL, BoomsmaDI, VandenbrouckeJP. Genetic influence on cytokine production and fatal meningococcal disease [published erratum appears in Lancet 1997;349:656] [see comments]. Lancet1997;349:170–173.
16.
LlorenteL, Richaud-PatinY, CoudercJ, Alarcon-SegoviaD, Ruiz-SotoR, Alcocer-CastillejosN, Alcocer-VarelaJ, GranadosJ, BahenaS, GalanaudP, EmilieD. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum1997;40:1429–1435.
17.
TanEM, CohenAS, FriesJF, MasiAT, McShaneDJ, RothfieldNF, SchallerJG, TalalN, WinchesterRJ. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982;25:1271–1277.
18.
GladmanD, GinzlerE, GoldsmithC, FortinP, LiangM, UrowitzM, BaconP, BombardieriS, HanlyJ, HayE, IsenbergDA, JonesJ, KalunianK, MaddisonP, NivedO, PetriM, RichterM, Sanchez-GuerreroJ, SnaithM, SturfeltG, SymmonsD, ZomaA. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum1996;39:363–369.
19.
BombardierC, GladmanDD, UrowitzMB, CaronD, ChangCH, Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum1992;35:630–640.
20.
RoodMJ, KeijsersV, van der LindenMW, TongTQ, BorggreveSE, VerweijCL, BreedveldFC, HuizingaTW. Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann Rheum Dis1999;58:85–89.
21.
VerduynW, DoxiadisII, AnholtsJ, DrabbelsJJ, NaipalA, D'AmaroJ, PersijnGG, GiphartMJ, SchreuderGM. Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in eurotransplant. Hum Immunol1993;37:59–67.
22.
KirchnerH, KleinickeCh, DigelW. A whole blood technique for testing production of human interferon by leukocytes. J Immunol Methods1982;48:213–219.
23.
DeschCE, KovachNL, PresentW, BroylesC, HarlanJM. Production of human tumor necrosis factor from whole blood ex vivo. Lymphokine Res1989;8:141–146.
24.
OliverJC, BlandLA, OettingerCW, ArduinoMJ, McAllisterSK, AgueroSM, FaveroMS. Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res1993;12:115–120.
25.
Finch-AriettaMB, CochranFR. Cytokine production in whole blood ex vivo. Agents Actions1991;34:49–52.
26.
de GrooteD, ZangerlePF, GevaertY, FassotteMF, BeguinY, Noizat-PirenneF, PirenneJ, GathyR, LopezM, DehartI, IgotD, BaudrihayeM, DelacroixD, FranchimontP. Direct stimulation of cytokines (il-1b, TNF-a, il-6, il-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine1992;4:239–248.
27.
ParkYB, LeeSK, KimDS, LeeJ, LeeCH, SongCH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol1998;16:283–288.
28.
RowlandT, McHughSM, DeightonJ, DearmanRJ, EwanPJ, KimberI. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology1998;40:11–20.
TanakaK, NishigouriS, KamedaS, KajiyamaK, KunihiroK, JimiS, TokudomeS, YamaguchiM. Decreased mortality among relatives of patients with systemic lupus erythematosus. Am J Epidemiol1983;118:728–731.
31.
DeanG, Tyrell-PriceJ, CrawleyE, IsenbergDA. Cytokines and systemic lupus erythematosus. Ann Rheum Dis2000;59:243–251.
32.
WilsonAG, de VriesN, PociotF, de GiovineFS, van der PutteLBA, DuffGW. An allelic polymorphism within the human TNF-alpha promoter region is strongly associated with HLA A1, B8 and DR3 alleles. J Exp Med1993;177:557–560.
33.
RoodMJ, van KrugtenMV, van der LindenMW, KeijsersV, SchreuderGMT, VerduynW, WestendorpRGJ, de VriesRRP, BreedveldFC, VerweijCL, HuizingaTWJ. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum2000;43:129–134.
34.
TurnerDM, WilliamsDM, SankaranD, LazarusM, SinnotPJ, HutchinsonIV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet1997;24:1–8.
35.
KeijsersV, TongTQ, VerweijCL, HazesJM, WestendorpRGJ, HuizingaTWJ. Innate differences in IL-10 production are present at the level of transcription and associated with haplotypes: Association of IL-10 haplotypes and rheumatoid arthritis (RA). Arthritis Rheum1998; 41:S188. Abstract.
36.
MokCC, LanchburyJS, Wai ChanD, Sing LauC. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum1998;41:1090–1095.
37.
EskdaleJ, GallagherG, VerweijCL, KeijsersV, WestendorpRG, HuizingaTW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A1998;95:9465–9470.
38.
EskdaleJ, WordsworthP, BowmanS, FieldM, GallagherG. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus [published erratum appears in Tissue Antigens 1997;50:699]. Tissue Antigens1997;49:635–639.
